logo

Blueprint Medicines (BPMC)



Trade BPMC now with
  Date
  Headline
8/2/2022 7:15:53 AM Blueprint Medicines Q2 Loss/shr Widens To $2.68 From $1.86 Last Year
8/2/2022 7:00:00 AM Blueprint Medicines Reports Second Quarter 2022 Results (Press Release)
6/30/2022 7:36:05 AM Royalty Pharma Buys Ex-U.S. Royalty Interest In Gavreto From Blueprint Medicines For Up To $340 Mln
6/30/2022 7:18:03 AM Blueprint Medicines Announces $1.25 Bln Strategic Financing Collaborations With Sixth Street And Royalty Pharma
6/23/2022 4:29:37 PM Blueprint Medicines Appoints Habib Dable To Its Board Of Directors
6/9/2022 7:09:30 AM Blueprint Medicines Provides Updates On AYVAKIT®/AYVAKYT® Development Program In Systemic Mastocytosis
3/25/2022 10:16:27 AM Blueprint Medicines' AYVAKYT Gets EC Approval For Treatment Of Adults With Advanced Systemic Mastocytosis
2/28/2022 4:58:06 PM Wedbush Reiterates Blueprint Medicines (BPMC) At Outperform With $126 Price Target
2/28/2022 8:17:25 AM Blueprint Medicines And Proteovant Therapeutics Collaborate To Advance Novel Targeted Protein Degrader Therapies
2/16/2022 5:16:53 PM Wedbush Is Cutting Blueprint Medicines (BPMC) FY22 Rev. Estimate To 190.0 M From 218.7 M
2/16/2022 5:16:38 PM Wedbush Is Raising Blueprint Medicines (BPMC) Q4 22 Rev. Estimate To 52.0 M From 50.5 M
2/16/2022 5:16:26 PM Wedbush Is Cutting Blueprint Medicines (BPMC) Q3 22 Rev. Estimate To 53.4 M From 63.8 M
2/16/2022 5:16:12 PM Wedbush Is Lowering Blueprint Medicines (BPMC) Q2 22 Rev. Estimate To 44.9 M From 56.8 M
2/16/2022 5:16:00 PM Wedbush Is Cutting Blueprint Medicines (BPMC) Q1 22 Rev. Estimate To 39.6 M From 47.7 M
2/16/2022 5:15:32 PM Wedbush Is Lowering Blueprint Medicines (BPMC) FY22 Estimate To -6.89 From -6.16
2/16/2022 5:15:14 PM Wedbush Is Cutting Blueprint Medicines (BPMC) Q4 22 Estimate To -1.77 From -1.72